1.Stratified therapeutic choices in elderly patients with diffuse large B-cell lymphoma
Journal of International Oncology 2021;48(5):317-320
The prognosis of elderly (>60 years) patients with diffuse large B-cell lymphoma (DLBCL) is significantly worse compared with young patients, and there is currently no standard treatment. Elderly patients with DLBCL are highly heterogeneous, a stratification before treatment can help achieve precise medicine and improve outcome of them. R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone) is still the recommended treatment for fit elderly DLBCL patients; and for unfit or very old patients, chemotherapy of reduced dose or palliative treatments should be considered. Choices for relapsed or refractory patients are limited, and novel compounds or therapies that are well tolerated may have a good application prospect.
2.Genetic variation of 9 X-linked short tandem repeat loci among four populations of Inner Mongolian.
Xiao-zhong LI ; Mu-er TONG ; La OU ; Ran ZHANG ; Liao-jiang RONG ; Qiao-fang HOU ; Bin YU ; Sheng-bin LI
Chinese Journal of Medical Genetics 2008;25(1):89-92
OBJECTIVETo investigate the genetic structure of X chromosome in Mongolia, Ewenki, Elunchun and Dawoer in Inner Mongolia.
METHODSNine short tandem repeat (STR) markers on the X chromosome (DXS6789, DXS101, DXS8378, DXS7132, DXS7133, DXS7423, DXS6804, DXS6799 and HPRTB) were analyzed in the four populations from Inner Mongolian (Mongol, Ewenki,Oroqen and Daur) for their genetic diversity, forensic suitability and possible genetic affinities of the populations. Frequencies and other parameters of forensic interest were computed.
RESULTSThe results revealed that the nine markers described here have a moderate degree of variability in the population groups. And there are significant differences in the genetic variability among the populations. Genetic distance and cluster analyses show very low genetic distance between Mongol and Han (Xi'an) communities. The results based on genetic distance analyses are consistent with earlier studies based on linguistic as well as immigration history and origin of these populations.
CONCLUSIONThe nine STR loci studied here were found not only useful in studying genetic variations between populations but also suitable for human identity testing.
China ; ethnology ; Chromosomes, Human, X ; genetics ; Cluster Analysis ; Ethnic Groups ; genetics ; Female ; Genetic Variation ; Humans ; Male ; Microsatellite Repeats ; genetics
3.Genetic structure of X-STR loci of Ewenki nationality and its affinity with other nationalities.
Qiao-Fang HOU ; Xiao-Zhong LI ; Mu-Er TONG ; Liao-Jiang RONG ; Ran ZHANG ; Xu-Jun WANG ; Sheng-Bin LI
Journal of Central South University(Medical Sciences) 2007;32(2):276-281
OBJECTIVE:
To determine the genetic diversity of X-TR loci, and to evaluate the genetic structure X chromosome's of Ewenki nationality and its affinity with other nationalities.
METHODS:
We chose 9 X-TR (DXS6804, DXS7133, DXS101, DXS6789, DXS6799, DXS7423, HPRTB, DXS8378, DXS7132) as genetic markers from 99 irrelative individules to determine the genetic diversity of Ewenki in Inner Mongolian. Cluster analysis and phylogenic trees was applied to show the genetic distance among the nationalities.
RESULTS:
We got 51 alleles in the studied population, with the frequency diverse between 0.0109 and 0.6863. Genotype frequency was from 0.0217 to 0.3778. Heterozygosity(H),the power of discrimination(PD) and the polymorphism information conten (PIC) were consistent with the forensic application. Cluster analysis and phylogenic trees revealed that Ewenki nationality had estrangement genetic affinity with the other 3 major nationalities in inner mongolia and Han nationality in Xi'an.
CONCLUSION
The genetic information demonstrates that the 9 chosen gene makers were highly informative loci and are suitable for population genetics research and forensic application.
China
;
Chromosomes, Human, X
;
genetics
;
Cluster Analysis
;
Ethnic Groups
;
classification
;
genetics
;
Female
;
Gene Frequency
;
Genetic Markers
;
genetics
;
Genetic Variation
;
Genotype
;
Humans
;
Male
;
Microsatellite Repeats
;
genetics
;
Phylogeny
;
Polymorphism, Genetic
4.Autologous stem cell transplantation for adult patients with acute lymphoblastic leukemia and related prognostic factors.
Shu-lian CHEN ; Rong-li ZHANG ; Jian-feng YAO ; Er-lie JIANG ; Qiao-ling MA ; Ai-ming PANG ; Si-zhou FENG ; Ming-zhe HAN
Chinese Journal of Hematology 2013;34(3):208-212
OBJECTIVEThis study was aimed to observe the efficacy of autologous stem cell transplantation (ASCT) for adult patients with acute lymphoblastic leukemia (ALL), and investigate related prognostic factors.
METHODSA total of 86 adult ALL patients underwent ASCT in Institute of Hematology and Blood Disease Hospital from November 2001 to January 2012 were followed up. Clinical characteristics and outcomes of all patients were retrospectively analyzed. Survival and univariate prognosis were analyzed by the Kaplan-Meier method and multivariate analysis by COX regression model.
RESULTSOutcomes were assessed in 81 cases, including 47 standard-risk and 34 high-risk patients. 1-, 3-, 5-, and 10-year leukemia-free survival (LFS) of standard-risk patients were (82.3±5.7)%, (76.9±6.5)%, (74.1±6.8)%, (67.4±8.9)% respectively,and relapse rates (RR) were as of (13.6±5.2)%, (21.6±6.4)%, (24.5±6.8)%, (31.3±9.0)% respectively. 1-, 3-, 5-, and 10-year LFS of high-risk patients were (55.8±8.9)%, (39.8±9.3)%, (39.8±9.3)%, (39.8±9.3)% respectively, and relapse rates (RR) were (38.8±9.2)%, (56.4±10.0)%, (56.4±10.0)%, (56.4±10.0)% respectively. T-ALL, white blood cell count(WBC) more than 30×109/L when first visited, increased LDH, positive fusion gene of TCR and bone marrow transplantation were the adverse prognostic factors. Multivariate analysis showed bone marrow transplantation was an independent adverse prognostic factor.
CONCLUSIONASCT was a choice for adult ALL patients when suitable donors were unavailable.
Adolescent ; Adult ; Female ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation ; Humans ; Male ; Middle Aged ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; therapy ; Prognosis ; Retrospective Studies ; Risk Factors ; Transplantation, Autologous ; Young Adult
5.Analyses of risk factors for intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Fa-hong YAN ; Mei WANG ; Yong HUANG ; Er-lie JIANG ; Qiao-ling MA ; Jia-lin WEI ; Ai-ming PANG ; Rong-li ZHANG ; Si-zhou FENG ; Ming-zhe HAN
Chinese Journal of Hematology 2013;34(12):1020-1023
OBJECTIVETo investigate the risk factors of intestinal acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODSThe clinical data of 534 cases of 533 patients undergoing allo-HSCT during Jan 2004 and Sep 2012 were retrospectively analyzed. The effects of donor-recipient HLA mismatching, recipient age, donor age, donor-recipient sex combination, donor-recipient relationship, HSC source, conditioning regimen with or without total body irradiation (TBI) and HLA loci on intestinal aGVHD with different severity were analyzed by Logistic regression.
RESULTSIntestinal aGVHD occurred in 123(23.0%) cases, with 86(16.1%) cases of stage 1 intestinal aGVHD(16.1%) and 37(6.9%) cases of stage 2 to 4 intestinal aGVHD. Multivariate analysis showed that donor-recipient HLA mismatching (OR=2.519, P=0.002), increasing donor age (OR=1.034, P=0.003), female donor for male recipient (OR=1.855, P=0.007) were risk factors for intestinal aGVHD, HLA-B38 (OR=0.256, P=0.032) was its protective factor. Donor-recipient HLA mismatching (OR=2.799, P=0.011), increasing donor age (OR=1.045, P=0.012), HLA-A1 (OR=4.157, P=0.002), A30 (OR=3.143, P=0.005) were risk factors for stage 2 to 4 intestinal aGVHD.
CONCLUSIONOccurrence of intestinal aGVHD and its severity are associated with donor-recipient HLA mismatching, donor age, donor-recipient sex relationships and some HLA loci.
Adolescent ; Adult ; Child ; Child, Preschool ; Female ; Graft vs Host Disease ; epidemiology ; Hematopoietic Stem Cell Transplantation ; adverse effects ; Humans ; Intestinal Diseases ; epidemiology ; Male ; Middle Aged ; Retrospective Studies ; Risk Factors ; Tissue Donors ; Transplantation, Homologous ; adverse effects ; Young Adult
6.Efficacy of recombinant human coagulation factor Ⅶ and immunosuppressive agent in patients with acute intestinal graft versus host disease complicated with bleeding after allogeneic hematopoietic stem cell transplantation.
Xin CHEN ; Wei Hua ZHAI ; Qiao Ling MA ; Jian Feng YAO ; Gang LI ; Chen LIANG ; Er Lie JIANG ; Si Zhou FENG ; Ming Zhe HAN
Chinese Journal of Hematology 2018;39(2):156-158
7.Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Xiao Li ZHAO ; Er Lie JIANG ; Wei Hua ZHAI ; Qiao Ling MA ; Ai Ming PANG ; Jia Lin WEI ; Yi HE ; Dong Lin YANG ; Si Zhou FENG ; Ming Zhe HAN
Chinese Journal of Hematology 2019;40(6):467-471
Objective: To assess the efficacy and toxicity of decitabine-based conditioning regimen in patients with myelodysplastic syndrome (MDS) , acute myeloid leukemia secondary to MDS (MDS-AML) or chronic myelomonocytic leukemia (CMML) . Methods: From March 1, 2013 to May 25, 2015, 22 patients who underwent allogenic hematopoietic stem cell transplantation (allo-HSCT) with decitabine-based conditioning regimen were analyzed retrospectively. Results: ①22 patients, 14 males and 8 females with a median age of 42.5 (24-56) years old, were diagnosed as MDS (n=14) , CMML (n=4) , MDS-AML (n=4) . ②15 patients were treated with the conditioning regimen of decitabine combined with busulfan, cyclophosphamide, fludarabine, and cytarabine, the other 7 cases were treated with decitabine, busulfan, fludarabine, and cytarabine. The dose of decitabine was 20 mg·m(-2)·d(-1) for 5 days.Rabbit anti-human anti-thymocyte globulin (2.5 mg·kg(-1)·d(-1) for 4 days) was involved in conditioning regimen in patients with unrelated donor or haploidentical transplantation. ③Except 1 patient died of infection in 2 months after transplantation, the other patients were engrafted successfully. The median time of granulocyte engraftment was 13 (12-18) days, and the median time of platelet engraftment was 16 (13-81) days. ④The incidence of acute graft versus host disease (aGVHD) was (41.3±10.6) %, and severe aGVHD (grade of III-IV) was (18.4±9.7) %. The incidence of chronic graft versus host disease (cGVHD) was (56.4±11.3) %, and extensive cGVHD was (36.4±12.1) %. ⑤8 patients were suffered with cytomegalovirus (CMV) viremia. Among the 18 patients with definitely infection, 6 occurred during myelosuppression and 12 cases occurred after hematopoietic reconstruction. The 2-year and 3-year non-relapse mortality was (13.9±7.4) % and (24.3±9.5) %, respectively. ⑥The 2-year and 3-year overall survival (OS) was (77.3±8.9) % and (67.9±10.0) %, respectively. The 2-year and 3-year relapse-free survival (RFS) was (72.7±9.5) % and (63.6±10.3) %, respectively. Conclusions: allo-HSCT with decitabine-based conditioning regimen is feasible in the treatment of MDS, MDS-AML or CMML.
Adult
;
Busulfan
;
Decitabine
;
Female
;
Graft vs Host Disease
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Leukemia, Myeloid, Acute
;
Leukemia, Myelomonocytic, Chronic
;
Male
;
Middle Aged
;
Myelodysplastic Syndromes
;
Retrospective Studies
;
Transplantation Conditioning
;
Transplantation, Homologous
;
Young Adult
8.Prognostic significance of early phase donor chimerism after allogeneic peripheral blood stem cell transplantation.
Wei Hua ZHAI ; Qing Zhen LIU ; Yuan Yuan SHI ; Gang LI ; Jia Li SUN ; Xin CHEN ; Jian Feng YAO ; Xiu Hua SU ; Qiao Ling MA ; Ai Ming PANG ; Yi HE ; Dong Lin YANG ; Rong Li ZHANG ; Yong HUANG ; Jia Lin WEI ; Si Zhou FENG ; Ming Zhe HAN ; Er Lie JIANG
Chinese Journal of Hematology 2018;39(11):932-936
Objective: To evaluate the prognostic significance of early phase full donor chimerism (FDC) after myeloablative allogeneic peripheral blood stem cell transplantation (allo-PBSCT). Methods: The clinical data of 72 hematological patients received myeloablative allo-PBSCT from Feb. 2016 to Jul. 2017 were analyzed retrospectively. The median age was 36.5 years (range 4-59), 44 were males and 28 females. Of the donors, there were 35 HLA matched sibling donors, 27 haploidentical donors and 10 unrelated donors. Polymerase chain reaction amplification of short tandem repeat sequence (PCR-STR) was used to detect donor cell chimerism (DC) rate of recipient bone marrow at one, two and three months after transplantation. Results: The median follow-up was 462 d (range: 47-805 d), 55 cases were still alive, and 45 cases were disease-free survival (DFS) at the end of follow-up. The 2-year overall survival (OS) and DFS were (68.9±7.7)% and (59.5±6.3)%, respectively. A number of 16 cases underwent relapses, with 2-year cumulative incidence of (24.1±5.3)%. The median time of recurrence was 157(32-374) d. Forty cases (55.6%) developed acute graft-versus-host diseases (aGVHD), with median time of 35.5 (13-90) d. Chronic GVHD (cGVHD) occurred in 23 patients (31.9%), with median time of 169 (94-475) d. Univariate analysis found the following factors were not related to OS, DFS or relapse rate (RR), including age, sex, blood type and sex of donor-recipient, occurrence of aGVHD and cGVHD. The OS and DFS in cases reached FDC and no FDC at two months after transplantation were (85.2±6.9)% vs (66.1±7.7)% (P=0.051) and (76.7±7.7)% vs (48.9±8.1)% (P=0.021), respectively. The RR rate in FDC group was lower than that in no FDC group [(16.6±6.8)% vs (30.4±7.8)%, P=0.187, respectively]. Conclusion: The present study confirmed the important value for predicting the prognosis with whether or not the patients reached FDC at the early phase after allo-PBSCT. The OS and DFS in cases with FDC at two months after transplantation were significantly higher than those of no FDC patients.
Adolescent
;
Adult
;
Child
;
Child, Preschool
;
Chimerism
;
Female
;
Graft vs Host Disease
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Male
;
Middle Aged
;
Peripheral Blood Stem Cell Transplantation
;
Prognosis
;
Retrospective Studies
;
Young Adult
9.Risk factors and prognosis of invasive fungal infections in patients with hematological diseases.
A-Xia SONG ; Yong HUANG ; Dong-Lin YANG ; Jia-Lin WEI ; Zhang-Song YAN ; Mei WANG ; Er-Lie JIANG ; Ai-Ming PANG ; Qiao-Ling MA ; Wei-Hua ZHAI ; Rong-Li ZHANG ; Si-Zhou FENG ; Ming-Zhe HAN
Chinese Journal of Hematology 2011;32(8):507-511
OBJECTIVETo investigate the incidence, risk factors, prognosis and high risk patients of invasive fungal infections (IFI) in patients with hematological diseases.
METHODS: Over 2-week hospitalized patients from January 2007 to December 2008 were retrospectively reviewed. Logistic regression was used to analyze the risk factors of IFI, and recursive partitioning to reveal high risk patients. Incidence of IFI was estimated by cumulative incidence function, and the prognosis by Kaplan-Meier method.
RESULTSA total of 1048 assessable treatment cycles were recorded and 93 cases of IFI were diagnosed, with an incidence of 8.87 per 100 treatment cycles. Multivariate logistic regression revealed the following risk factors: age (OR 1.025, 95% CI 1.010-1.041, P = 0.002), duration of neutropenia (OR 1.028, 95% CI 1.014-1.042, P < 0.0001) and uncontrolled underlying diseases (OR 2.620, 95% CI 1.608-4.268, P = 0.0001). Recursive partitioning found two groups of high risk patients: (1) patients with uncontrolled underlying diseases and neutropenia duration > or = 58 days (7/12, 58.3%), (2) patients with uncontrolled underlying diseases and age > or = 33 years (40/208, 19.2%). At the end of follow-up, 111 cases of IFI were recorded in 451 patients, with a 1-year cumulative incidence of 27.1%. In patients with established IFI, overall survival rate and IFI related mortality rate at 12 weeks after diagnosis were 83.4% and 13.5% respectively.
CONCLUSIONAge, duration of neutropenia and uncontrolled underlying diseases are risk factors of IFI; patients with uncontrolled underlying diseases and age > or = 33 years were at high risk of IFI and need major concern. IFI has a better prognosis and a lower related mortality in this study.
Female ; Hematologic Diseases ; diagnosis ; microbiology ; therapy ; Hematopoietic Stem Cell Transplantation ; Humans ; Incidence ; Logistic Models ; Male ; Multivariate Analysis ; Mycoses ; epidemiology ; Prognosis ; Retrospective Studies ; Risk Factors
10.Preliminary analysis of therapeutic efficacy and prognosis of allogeneic hematopoietic stem cell transplantation in patients with advanced chronic myeloid leukemia.
A-Xia SONG ; Dong-Lin YANG ; Jia-Lin WEI ; Zhang-Song YAN ; Mei WANG ; Er-Lie JIANG ; Yong HUANG ; Qiao-Ling MA ; Yi HE ; Wei-Hua ZHAI ; Rong-Li ZHANG ; Si-Zhou FENG ; Ming-Zhe HAN
Journal of Experimental Hematology 2011;19(1):149-153
Chronic myeloid leukemia (CML) at advanced and blastic phase is a disease with poor prognosis, for which allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment choice with curative potential. This study was purposed to investigate the therapeutic efficacy of allo-HSCT and prognosis of advanced CML patients. The 28 cases of CML in accelerated phase or blast crisis received allo-HSCT were analysed retrospectively in terms curative efficacy, basic characteristics before transplant and prognosis, therapeutic strategy before transplant and prognosis, events after transplant and prognosis. The results indicated that 10 out of 28 patients were in complete remission, showing a 3-year overall survival and disease-free survival rate of 34.9% and 35.7% respectively; 18 patients died. Univariate analysis revealed that the clonal evolution and blast amount are baseline risk factor of poor prognosis, and combination of them can be used to predict the outcome of patients; application of imatinib before transplant and achievement of complete hematologic remission could not improve the prognosis; severe aGVHD among post-transplant events was proven to be a negative prognostic factor. It is concluded that for advanced CML patients received allo-HSCT, clonal evolution and blast percentage are prognostic factors, and the pre-transplant use of imatinib did not influence the outcome.
Adolescent
;
Adult
;
Benzamides
;
Child
;
Child, Preschool
;
Female
;
Hematopoietic Stem Cell Transplantation
;
methods
;
Humans
;
Imatinib Mesylate
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
drug therapy
;
surgery
;
therapy
;
Male
;
Middle Aged
;
Piperazines
;
therapeutic use
;
Prognosis
;
Pyrimidines
;
therapeutic use
;
Retrospective Studies
;
Young Adult